<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842270</url>
  </required_header>
  <id_info>
    <org_study_id>AB04026</org_study_id>
    <nct_id>NCT00842270</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma</brief_title>
  <official_title>A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate, comparatively to a placebo, the activity of oral AB1010,
      administered at three dose levels during 4 months to patients with severe persistent
      corticosteroid dependent asthma, assessed on :

        -  the decrease in corticosteroid therapy

        -  the asthma control improvement (symptomatic scores, rescue medication intake,
           respiratory function)

        -  the pharmacokinetic profile of AB1010

        -  clinical and biological safety parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, parallel-groups, multicenter study of
      daily oral AB1010 at doses 3, 4.5 and 6 mg/kg/day.

      The study treatment is administered for 16 weeks:

        -  the first 4 weeks are a run-in period during which corticosteroids remain stable;

        -  during the following 8 weeks, corticosteroids are decreased every week until weaning or
           an exacerbation occurs;

        -  the last 4 weeks are a stabilization period. Patients have to perform a visit every 2
           weeks during run-in, then every week for the following 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in oral corticosteroid therapy (weaning extent)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>asthma control improvement</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asthma exacerbation rate</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4,5 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo for AB1010 3, 4,5 and 6 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB1010 3 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB1010</intervention_name>
    <description>3 mg/kg/day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>masitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB1010</intervention_name>
    <description>4,5 mg/kg/day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>masitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB1010</intervention_name>
    <description>6 mg/kg/day</description>
    <arm_group_label>3</arm_group_label>
    <other_name>masitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo to AB1010 dosages</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known severe persistent corticosteroid dependent asthma (WHO/NHLBI workshop
             definition).

          -  Disease duration &gt; 1 year.

          -  Stable disease with no exacerbation episode for at least one month before inclusion.

          -  Daily treated with 10 to 50 mg of equivalent prednisolone, with stable dosage since at
             least 3 months.

          -  Known reversibility of bronchial obstruction, defined as an enhancement of FEV1 â‰¥ 12%,
             10 minutes after salbutamol administration, or 14 days after systemic treatment with 1
             mg/kg/day of equivalent prednisolone.

        Exclusion Criteria:

          -  Asthmatic patients still exposed to allergens or to triggering factors influencing
             asthma control.

          -  History of infection requiring hospitalization or treatment with antibiotics within 2
             weeks of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alain Moussy</name_title>
    <organization>AB Science</organization>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>corticosteroids dependent</keyword>
  <keyword>asthma exacerbation</keyword>
  <keyword>weaning</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>severe persistent corticosteroid dependent asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

